血清miR-150-5p和miR-155-5p对老年糖尿病肾病的诊断价值
|
摘要
目的探讨血清miR-150-5p和miR-155-5p在老年糖尿病肾病(DN)中的表达水平及其诊断价值。方法采用实时定量PCR(RT-PCR)法检测2015年1月—2017年12月海南西部中心医院收治的126例老年DN患者(DN组)、140例2型糖尿病患者(2型糖尿病组)和65例健康体检者(对照组)的血清miR-150-5p和miR-155-5p水平。应用受试者工作特征(ROC)曲线分析血清miR-150-5p和miR-155-5p水平对老年DN患者的诊断价值。结果 DN组血清miR-150-5p(3.35±1.26)和miR-155-5p(5.47±1.80)表达水平均高于2型糖尿病组和对照组,差异有统计学意义(P<0.01)。2型糖尿病组与对照组血清miR-150-5p和miR-155-5p表达水平比较,差异无统计学意义(P>0.05)。ROC曲线分析显示,血清miR-150-5p和miR-155-5p诊断老年DN的最佳截值分别为2.65、4.16,灵敏度分别为82.7%和80.3%,特异度为74.8%和83.6%。二者联合诊断老年DN的AUC(95%CI)为0.892(0.834～0.953)优于单项miR-150-5p[0.805(0.749～0.865)]和miR-155-5p[0.837(0.779～0.894)](P<0.05),其灵敏度(90.4%)和特异度(85.7%)最好。结论血清miR-150-5p和miR-155-5p水平在老年DN患者中升高,有望作为老年DN诊断的生物学标志物。
Objective To investigate expression level and diagnostic value of serum miR-150-5p and miR-155-5p inelderly diabetic nephropathy(DN). Methods Serum miR-150-5p and miR-155-5p levels of 126 elderly DN patients(groupDN), 140 patients with type 2 diabetes mellitus(type 2 diabetes group) and 65 healthy persons(control group) were detected byreal-time quantitative PCR(RT-PCR) from January 2015 to December 2017. Diagnostic value of serum miR-150-5p andmiR-155-5p levels in elderly DN patients was analyzed by receiver operating characteristic(ROC) curve. Results Theexpression levels of serum miR-150-5p(3.35±1.26)and miR-155-5p(5.47±1.80)in group DN were significantly higher thanthose in type 2 diabetes group and control group(P<0.01). There was no significant difference in serum miR-150-5p and miR-155-5p levels between type 2 diabetes group and control group(P>0.05). The ROC curve analysis showed that the best cut-offvalues of serum miR-150-5p and miR-155-5p diagnosis of elderly DN were 2.65 and 4.16, respectively. The sensitivity were82.7% and 80.3%, and specificity were 74.8% and 83.6%, respectively. The two combined diagnosis of elderly DN of AUC(95%CI) [0.892(0.834-0.953)] were significantly better than miR-150-5p [0.805(0.749-0.865)] and miR-155-5p [0.837(0.779-0.894)](P<0.05), and its sensitivity(90.4%) and specificity(85.7%) were best. Conclusion Serum miR-150-5p andmiR-155-5p levels in elderly DN patients increase significantly, and it is expected to be a biomarker for the diagnosis of DN inelderly patients.
Objective To investigate expression level and diagnostic value of serum miR-150-5p and miR-155-5p inelderly diabetic nephropathy(DN). Methods Serum miR-150-5p and miR-155-5p levels of 126 elderly DN patients(groupDN), 140 patients with type 2 diabetes mellitus(type 2 diabetes group) and 65 healthy persons(control group) were detected byreal-time quantitative PCR(RT-PCR) from January 2015 to December 2017. Diagnostic value of serum miR-150-5p andmiR-155-5p levels in elderly DN patients was analyzed by receiver operating characteristic(ROC) curve. Results Theexpression levels of serum miR-150-5p(3.35±1.26)and miR-155-5p(5.47±1.80)in group DN were significantly higher thanthose in type 2 diabetes group and control group(P<0.01). There was no significant difference in serum miR-150-5p and miR-155-5p levels between type 2 diabetes group and control group(P>0.05). The ROC curve analysis showed that the best cut-offvalues of serum miR-150-5p and miR-155-5p diagnosis of elderly DN were 2.65 and 4.16, respectively. The sensitivity were82.7% and 80.3%, and specificity were 74.8% and 83.6%, respectively. The two combined diagnosis of elderly DN of AUC(95%CI) [0.892(0.834-0.953)] were significantly better than miR-150-5p [0.805(0.749-0.865)] and miR-155-5p [0.837(0.779-0.894)](P<0.05), and its sensitivity(90.4%) and specificity(85.7%) were best. Conclusion Serum miR-150-5p andmiR-155-5p levels in elderly DN patients increase significantly, and it is expected to be a biomarker for the diagnosis of DN inelderly patients.
引文
[1]HUANG Y Q,GOU R,DIAO Y S,et al.Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy[J].Journal of Zhejiang University SCIENCE B,2014,15(1):58-66.
[2]CHAN G,TANG S C.Current practices in the management of diabetic nephropathy[J].J R Coll Physicians Edinb,2013,43(4):330-333.
[3]ULLAH S,JOHN P,BHATTI A.MicroRNAs with a role in gene regulation and in human diseases[J].Molecular Biology Reports,2014,41(1):225-232.
[4]王勾琴,王俭勤,梁耀军,等.微小RNA在糖尿病肾病患者血清中的表达及临床意义[J].中华肾脏病杂志,2015,31(7):503-508.
[5]MARIO UNIGARRO.Diagnosis and classification of diabetes mellitus[J].Diabetes Care,2011,34(Supplement_1):S62-S69.
[6]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华内分泌代谢杂志,2014,30(10):893-942.
[7]MORENO-MOYA J M,VILELLA F,SIMóN C.MicroRNA:key gene expression regulators[J].Fertility and Sterility,2014,101(6):1516-1523.
[8]WU X B,XIA M,CHEN D Y,et al.Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma[J].Tumour Biol,2016,37(11):15019-15029.
[9]QU Y L,WANG H F,SUN Z Q,et al.Up-regulated miR-155-5p promotes cell proliferation,invasion and metastasis in colorectal carcinoma[J].Int J Clin Exp Pathol,2015,8(6):6988-6994.
[10]FIGUEIRA M F,MONNERAT-CAHLI G,MEDEI E,et al.MicroR-NAs:potential therapeutic targets in diabetic complications of the cardiovascular and renal systems[J].Acta Physiol(Oxf),2014,211(3):491-500.
[11]SIMPSON K,WONNACOTT A,FRASER D J,et al.MicroRNAs in diabetic nephropathy:from biomarkers to therapy[J].Current Diabetes Reports,2016,16(3):35.
[12]MCCLELLAND A D,KANTHARIDIS P.microRNA in the development of diabetic complications[J].Clinical Science,2014,126(2):95-110.
[13]ZHOU H,HASNI S A,PEREZ P,et al.Mir-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1[J].Journal of the American Society of Nephrology,2013,24(7):1073-1087.
[14]HUANG Y Q,LIU Y,LI L,et al.Involvement of inflammation-related miR-155 and miR-146a in diabetic nephropathy:implications for glomerular endothelial injury[J].BMC Nephrol,2014,15:142.
[15]SCHENA F P,SERINO G,SALLUSTIO F.MicroRNAs in kidney diseases:new promising biomarkers for diagnosis and monitoring[J].Nephrol Dial Transplant,2014,29(4):755-763.
[16]徐爽,梁琳琅,李萍,等.T2DM患者糖尿病肾病的危险因素分析[J].热带医学杂志,2017,17(3):370-372,396.2018-07-18
[2]CHAN G,TANG S C.Current practices in the management of diabetic nephropathy[J].J R Coll Physicians Edinb,2013,43(4):330-333.
[3]ULLAH S,JOHN P,BHATTI A.MicroRNAs with a role in gene regulation and in human diseases[J].Molecular Biology Reports,2014,41(1):225-232.
[4]王勾琴,王俭勤,梁耀军,等.微小RNA在糖尿病肾病患者血清中的表达及临床意义[J].中华肾脏病杂志,2015,31(7):503-508.
[5]MARIO UNIGARRO.Diagnosis and classification of diabetes mellitus[J].Diabetes Care,2011,34(Supplement_1):S62-S69.
[6]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华内分泌代谢杂志,2014,30(10):893-942.
[7]MORENO-MOYA J M,VILELLA F,SIMóN C.MicroRNA:key gene expression regulators[J].Fertility and Sterility,2014,101(6):1516-1523.
[8]WU X B,XIA M,CHEN D Y,et al.Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma[J].Tumour Biol,2016,37(11):15019-15029.
[9]QU Y L,WANG H F,SUN Z Q,et al.Up-regulated miR-155-5p promotes cell proliferation,invasion and metastasis in colorectal carcinoma[J].Int J Clin Exp Pathol,2015,8(6):6988-6994.
[10]FIGUEIRA M F,MONNERAT-CAHLI G,MEDEI E,et al.MicroR-NAs:potential therapeutic targets in diabetic complications of the cardiovascular and renal systems[J].Acta Physiol(Oxf),2014,211(3):491-500.
[11]SIMPSON K,WONNACOTT A,FRASER D J,et al.MicroRNAs in diabetic nephropathy:from biomarkers to therapy[J].Current Diabetes Reports,2016,16(3):35.
[12]MCCLELLAND A D,KANTHARIDIS P.microRNA in the development of diabetic complications[J].Clinical Science,2014,126(2):95-110.
[13]ZHOU H,HASNI S A,PEREZ P,et al.Mir-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1[J].Journal of the American Society of Nephrology,2013,24(7):1073-1087.
[14]HUANG Y Q,LIU Y,LI L,et al.Involvement of inflammation-related miR-155 and miR-146a in diabetic nephropathy:implications for glomerular endothelial injury[J].BMC Nephrol,2014,15:142.
[15]SCHENA F P,SERINO G,SALLUSTIO F.MicroRNAs in kidney diseases:new promising biomarkers for diagnosis and monitoring[J].Nephrol Dial Transplant,2014,29(4):755-763.
[16]徐爽,梁琳琅,李萍,等.T2DM患者糖尿病肾病的危险因素分析[J].热带医学杂志,2017,17(3):370-372,396.2018-07-18